Hormone Replacement Therapy in Military Women and Men: Benefits for Performance and Leadership
For female service members with menopausal symptoms, hormone therapy effectively treats vasomotor symptoms and genitourinary issues, improving quality of life and work performance, but should NOT be used for chronic disease prevention due to increased risks of breast cancer, cardiovascular events, and thromboembolism. 1, 2 For male service members with documented low testosterone and sexual dysfunction, testosterone therapy may provide modest improvement in sexual function but should NOT be initiated for energy, vitality, physical function, or cognition. 3
For Female Service Members
When HRT Provides Clear Benefit
Symptomatic relief is the primary—and essentially only—appropriate indication for HRT in military women:
- Vasomotor symptoms (hot flashes, night sweats): HRT is the most effective treatment available 2, 4
- Genitourinary syndrome of menopause: Low-dose vaginal estrogen preparations are highly effective for vaginal dryness, dyspareunia, and urinary symptoms 2
- Quality of life improvements: Modest benefits in sleep, mood, and sexual function when bothersome symptoms are present 4, 5
Critical Timing Considerations
The "timing hypothesis" is crucial for military personnel: Women who initiate HRT within 10 years of menopause onset or before age 60 have a more favorable risk-benefit profile than older women 4, 6. For service members experiencing early menopause (including surgical menopause from oophorectomy), HRT should be continued until approximately age 51—the natural age of menopause 7.
What HRT Does NOT Do (Despite Common Misconceptions)
The USPSTF explicitly recommends AGAINST routine HRT for chronic disease prevention (Grade D recommendation) 1. Do not prescribe HRT to military women for:
- Cardiovascular disease prevention (actually increases CHD risk, particularly in older women) 1
- Cognitive enhancement or dementia prevention (insufficient evidence) 1
- General "anti-aging" or performance enhancement
Quantifying the Risks
Per 10,000 women taking estrogen-progestin for 1 year 1:
- 7 additional coronary heart disease events
- 8 additional strokes
- 8 additional pulmonary emboli
- 8 additional invasive breast cancers
- BUT: 6 fewer colorectal cancers and 5 fewer hip fractures
The harms outweigh benefits when used for prevention in asymptomatic women.
Practical Prescribing Algorithm for Military Women
Step 1: Confirm bothersome menopausal symptoms (not just laboratory values)
Step 2: Screen for contraindications:
- Current or history of breast cancer
- Cardiovascular disease or stroke
- Active thromboembolism or thrombophilic disorder
- Active liver disease
- Unexplained vaginal bleeding
Step 3: Choose formulation based on risk profile:
- Transdermal estradiol (patch/gel) preferred over oral—lower VTE, stroke, and MI risk 7, 5
- Natural micronized progesterone preferred over synthetic progestogens—better breast safety profile 7, 5
- Vaginal estrogen only if symptoms are purely genitourinary 2
Step 4: Use lowest effective dose for shortest duration needed 1, 8, 9
Step 5: Reassess every 6-12 months; discontinue if symptoms resolve or risks emerge
Special Consideration: Testosterone for Women
Testosterone therapy in women may benefit those with hypoactive sexual desire disorder (HSDD) after menopause 10, 11, 12. However, no FDA-approved formulation exists for women in the United States 11, 12. The evidence supports modest improvements in sexual function but NOT for energy, cognition, or physical performance 11. Use should be limited to specialist settings with appropriate monitoring 7.
For Male Service Members
The Limited Role of Testosterone Therapy
The American College of Physicians provides clear, restrictive guidance 3:
Recommendation 1: Consider testosterone ONLY for men with age-related low testosterone AND sexual dysfunction who specifically want to improve sexual function (conditional recommendation, low-certainty evidence) 3
Recommendation 2: Do NOT initiate testosterone to improve energy, vitality, physical function, or cognition (conditional recommendation, low-certainty evidence) 3
What This Means for Military Men
Testosterone therapy will NOT enhance:
- Physical performance or strength
- Energy levels or endurance
- Cognitive function or decision-making
- Leadership capabilities
- Overall vitality
The evidence shows testosterone provides small improvements in sexual function only, with effect sizes that are modest at best 13, 14. Quality of life improvements are minimal 13.
Practical Approach for Male Service Members
Step 1: Document both:
- Persistently low serum testosterone (typically <300 ng/dL on two morning measurements)
- Specific symptoms of sexual dysfunction
Step 2: Rule out reversible causes:
- Obesity (weight loss often normalizes testosterone)
- Medications (opioids, glucocorticoids)
- Sleep apnea
- Chronic illness
Step 3: If initiating therapy:
- Intramuscular formulations preferred over transdermal—similar efficacy, much lower cost 3
- Reassess symptoms at 12 months
- Discontinue if no improvement in sexual function 3
Step 4: Monitor annually:
- Serum testosterone levels
- Hematocrit (risk of polycythemia)
- Prostate-specific antigen in men ≥40 years 14
Safety Considerations for Testosterone in Men
Recent large randomized trials show testosterone does NOT increase risk of myocardial infarction or stroke, even in high-risk men 14. However, long-term safety data beyond 1-2 years remain limited 13. The most common adverse effects are acne, polycythemia, and potential worsening of sleep apnea 14.
Common Pitfalls to Avoid
Do not prescribe HRT to women for "prevention"—the USPSTF explicitly recommends against this 1
Do not prescribe testosterone to men for "low energy" or "performance enhancement"—no evidence of benefit 3, 13
Do not rely solely on laboratory values—symptom-based assessment is more reliable, particularly in women 11
Do not use oral estrogen in women with cardiovascular or thrombotic risk—transdermal route is safer 7, 5
Do not continue therapy indefinitely without reassessment—risks increase with duration, particularly for breast cancer in women 1, 4